Related Experiment Videos
The drug treatment of atrial fibrillation
1Department of Cardiology, Royal Hallamshire Hospital, Sheffield.
Insights
Atrial fibrillation management involves cardioversion for rhythm control or rate control strategies for chronic cases. Anticoagulation or aspirin is crucial for preventing thromboembolism in chronic atrial fibrillation.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Atrial fibrillation (AF) is a common arrhythmia causing symptoms like dyspnea and palpitations.
- AF significantly increases the risk of thromboembolic events.
Purpose of the Study:
- To outline current management strategies for atrial fibrillation.
- To discuss options for rhythm control, rate control, and thromboembolism prophylaxis.
Main Methods:
- Review of pharmacological and electrical cardioversion techniques.
- Discussion of antiarrhythmic drug classes (Ic, III) for prophylaxis.
- Evaluation of agents for atrioventricular node modulation (digoxin, CCBs, beta-blockers).
- Consideration of anticoagulation and antiplatelet therapy.
Main Results:
- Cardioversion (electrical or pharmacological with Class Ic drugs) is an initial management option.
- Class Ic or Class III drugs (sotalol, amiodarone) are recommended for paroxysmal AF prophylaxis.
- Ventricular rate control in chronic AF can be achieved with digoxin, calcium channel blockers, or beta-blockers.
- Anticoagulation or aspirin is advised for chronic AF due to high thromboembolism risk.
Conclusions:
- Management strategies for atrial fibrillation depend on the type (paroxysmal vs. chronic) and patient factors.
- Rhythm control, rate control, and thromboembolism prevention are key therapeutic goals.
- Pharmacological and non-pharmacological interventions are available for comprehensive AF management.
Abstract:
1. Atrial fibrillation is an inefficient cardiac rhythm associated with impaired exercise tolerance, exertional dyspnoea, palpitation and a substantial risk of thromboembolism. 2. The first decision in management is to consider cardioversion which can be achieved in suitable cases electrically, or pharmacologically with a class Ic antiarrhythmic drug like flecainide or propafenone. 3. Prophylaxis in paroxysmal atrial fibrillation is best achieved with a class Ic drug or a class III drug such as sotalol or amiodarone. 4. Control of ventricular rate in chronic atrial fibrillation can be achieved by pharmacological manipulation of the atrioventricular node by digoxin alone, or in combination with the calcium channel blockers verapamil or diltiazem, or beta-adrenoceptor blockers with intrinsic sympathomimetic activity like pindolol or xamoterol. 5. In view of the considerable risk of thromboembolism in patients with chronic atrial fibrillation anticoagulation or at least treatment with aspirin should be considered.